Anemia and stroke: Where do we stand?

Acta Neurologica Scandinavica

Volumn 135, Issue 6, 2017, Pages 596-602

  Kaiafa, G ^a   Savopoulos, C ^a   Kanellos, I ^a   Mylonas, K S ^a   Tsikalakis, G ^a   Tegos, T ^a   Kakaletsis, N ^a   Hatzitolios, A I ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

anemia; erythropoietin; iron deficiency anemia; sickle cell anemia; stroke; thalassemia

Indexed keywords

ANEMIA; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; REVIEW; BLOOD; METABOLISM;

HEMOGLOBIN;

ANEMIA; HEMOGLOBINS; HUMANS; STROKE;

EID: 84994632790     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12657     Document Type: Review

References (52)

1. Dubyk MD, Card RT, Whiting SJ, et al. Iron deficiency anemia prevalence at first stroke or transient ischemic attack. Can J Neurol Sci. 2012;39:189–195.
2. Spence RK. The economic burden of anemia in heart failure. Heart Fail Clin. 2010;6:373–383.
3. Kaiafa G, Kanellos I, Savopoulos C, Kakaletsis N, Giannakoulas G, Hatzitolios AI. Is anemia a new cardiovascular risk? Int J Cardiol. 2015;186:117–124.
4. Del Fabbro P, Luthi JC, Carrera E, Michel P, Burnier M, Burnand B. Anemia and chronic kidney disease are potential risk factors for mortality in stroke patients: a historic cohort study. BMC Nephrol. 2010;16:11–27.
5. Hao Z, Wu B, Wang D, Lin S, Tao W, Liu M. A cohort study of patients with anemia on admission and fatality after acute ischemic stroke. J Clin Neurosci. 2013;20:37–42.
6. Kannel WB, Gordon T, Wolf PA, McNamara P. Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke. 1972;3:409–420.
7. Artigao-Rodenas LM, Carbayo-Herencia JA, Divisón-Garrote JA, et al. Framingham risk score for prediction of cardiovascular diseases: a population-based study from southern Europe. PLoS ONE. 2013;8:e73529.
8. Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: Does hemoglobin change with aging? Semin Hematol. 2015;52:261–269.
9. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
10. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol. 2002;40:27–33.
11. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064–2089.
12. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
13. Powers WJ, Derdeyn CP, Biller J, et al. American Heart Association/American Stroke Association Focused Update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020–3035.
14. Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron-deficiency anemia and thrombocytosis. Stroke. 1996;27:1002–1005.
15. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet. 2010;376(9735):112–123.
16. Huang WY, Chen IC, Meng L, Weng WC, Peng TI. The influence of anemia on clinical presentation and outcome of patients with first-ever atherosclerosis-related ischemic stroke. J Clin Neurosci. 2009;16:645–649.
17. Milionis H, Papavasileiou V, Eskandari A, D'Ambrogio-Remillard S, Ntaios G, Michel P. Anemia on admission predicts short- and long-term outcomes in patients with acute ischemic stroke. Int J Stroke. 2015;10:224–230.
18. Wong TY, Klein R, Sharrett AR, et al. ARIC Investigators. Atherosclerosis Risk in Communities Study. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 2002;288:67–74.
19. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009;114:5117–5125.
20. Ali N, Srey R, Pavlakis S. Hemoglobinopathies and stroke: strategies for prevention and treatment. Curr Treat Options Cardiovasc Med. 2012;14:227–236.
21. Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics. 2007;120:1053–1057.
22. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol. 1997;16:50–53.
23. Azab SF, Abdelsalam SM, Saleh SH, et al. Iron deficiency anemia as a risk factor for cerebrovascular events in early childhood: a case–control study. Ann Hematol. 2014;93:571–576.
24. Chang YL, Hung SH, Ling W, Lin HC, Li HC, Chung SD. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PLoS ONE. 2013;8:82952.
25. Chan T, Ganasekaran G. The effect of anemia on the functional outcomes of the stroke patients and the efficiency of their stroke rehabilitation. J Stroke Cerebrovasc Dis. 2015;24:1438–1442.
26. Nouh A, Hussain M, Mehta T, Yaghi S. Embolic strokes of unknown source and cryptogenic stroke: implications in clinical practice. Front Neurol. 2016;7:37.
27. Yager JY, Hartfield DS. Neurologic manifestations of iron deficiency in childhood. Pediatr Neurol. 2002;27:85–92.
28. McCombe PA, Read SJ. Immune and inflammatory responses to stroke: Good or bad? Int J Stroke. 2008;3:254–265.
29. Quinn CT, McKinstry RC, Dowling MM, et al. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013;70:58–65.
30. Choi SH, Choi-Kwon S, Kim MS, Kim JS. Poor nutrition and alcohol consumption are related to high serum homocysteine level at post-stroke. Nutr Res Pract. 2015;9:503–510.
31. Neogi SS, Thomas M, Sharma A, Kumar J, Khanduri U. Early markers of occult megaloblastosis for low-cost detection of hyperhomocysteinemia in patients with ischaemic stroke: preventive approach for primary health care. Can J Physiol Pharmacol. 2014;92:713–716.
32. Zeng YJ, Liu GF, Liu LP, Wang CX, Zhao XQ, Wang YJ. Anemia on admission increases the risk of mortality at 6 months and 1 year in hemorrhagic stroke patients in China. J Stroke Cerebrovasc Dis. 2014;23:1500–1505.
33. Todd MM, Wu B, Warner DS, et al. The hemispheric cerebrovascular response to hemodilution is attenuated by a focal cryogenic brain injury. J Neurotrauma. 1994;11:149–160.
34. Reasoner DK, Ryu KH, Hindman BJ, Cutkomp J, Smith T. Marked hemodilution increases neurologic injury after focal cerebral ischemia in rabbits. Anesth Analg. 1996;82:61–67.
35. Shahar A, Sadeh M. Severe anemia associated with transient neurological deficits. Stroke. 1991;22:1201–1202.
36. Hsiao KY, Hsiao CT, Lin LJ, Shiao CJ, Chen IC. Severe anemia associated with transient ischemic attacks involving vertebrobasilar circulation. Am J Emerg Med. 2008;26:382.e3-4.
37. Sheth KN, Gilson AJ, Chang Y, et al. Packed red blood cell transfusion and decreased mortality in intracerebral hemorrhage. Neurosurgery. 2011;68:1286–1292.
38. Lapchak PA. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!. Expert Opin Investig Drugs. 2010;19:1179–1186.
39. Kellert L, Schradera F, Ringleb P, Steiner T, Bösel B. The impact of low hemoglobin levels and transfusion on critical care patients with severe ischemic stroke. STroke: RelevAnt Impact of HemoGlobin, Hematocrit and Transfusion (STRAIGHT)—an observational study. Stroke. 2014;29:236–240.
40. LeRoux P. Haemoglobin management in acute brain injury. Curr Opin Crit Care. 2013;19(2):83–91.
41. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526–10531.
42. Ntaios G, Savopoulos C, Chatzinikolaou A, Hatzitolios AI. The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: from bench to bedside. Acta Neurol Scand. 2008;118:362–366.
43. Bailey DM, Robach P, Thomsen JJ, Lundby C. Erythropoietin depletes iron strokes: antioxidant neuroprotection for ischemic stroke? Stroke. 2006;37:2453.
44. Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002;952:128–134.
45. Veys N, Van Biesen W, Lameire N, et al. Internal medicine, renal anemia and erythropoiesis-stimulating agents (ESAs). Acta Clin Belg. 2007;62:396–407.
46. Benedict SL, Bonkowsky JL, Thompson JA, et al. Cerebral sinovenous thrombosis in children: another reason to treat iron deficiency anemia. J Child Neurol. 2004;19:526–531.
47. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Follow up Study. National Health and Nutrition Examination Survey. Am J Epidemiol. 1996;144:59–68.
48. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–1227.
49. Day SM, Duquaine D, Mundada LV, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;20:2601–2606.
50. van der ADL, Grobbee DE, Roest M, Marx JJ, Voorbij HA, van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005;36:1637–1641.
51. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol. 2008;19:1817–1826.
52. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.